<DOC>
	<DOCNO>NCT01765400</DOCNO>
	<brief_summary>The investigator aim determine patient systolic heart failure treat prasugrel achieve great platelet inhibition compare treated clopidogrel .</brief_summary>
	<brief_title>Platelet Inhibition Patients With Systolic Heart Failure</brief_title>
	<detailed_description>Thienopyridine antiplatelet agent important component therapy management acute coronary syndrome ( ACS ) . Dual antiplatelet therapy thienopyridine , commonly clopidogrel , aspirin widely use management ACS prevent major adverse cardiovascular event . Despite benefit regimen , many patient continue develop atherothrombotic event regimen . Various reason include inter-patient variability , delay onset action , obtainable antiplatelet activity clopidogrel describe potential cause limited efficacy prevent recurrent event . The Trial ass improvement therapeutic outcome optimize platelet inhibition prasugrelâ€”thrombolysis myocardial infarction ( TRITON-TIMI 38 ) show patient moderate-to-high-risk ACS schedule percutaneous coronary intervention ( PCI ) treat prasugrel decrease cardiovascular event compare clopidogrel . Clopidogrel prodrug require two hepatic conversion step cytochrome ( CYP ) P450 enzyme system . The need CYP450 involvement know contribute variable response platelet inhibition demonstrate clopidogrel . Although prasugrel also thienopyridine , require hepatic CYP450 enzymes one conversion step , convert active metabolite efficiently . Therefore , prasugrel provide significantly potent platelet inhibition compare clopidogrel . Patients advance systolic heart failure commonly elevate hepatic venous pressure cause hepatic congestion hypoperfusion result impaired hepatic function . The elevated hepatic venous pressure predominantly affect hepatic centrilobular cell contain high concentration cytochrome P-450 ( CYP450 ) enzyme system . Hence patient advance heart failure may convert less clopidogrel active metabolite subsequently produce less platelet inhibition compare prasugrel . Since prasugrel require CYP450 system one conversion step , impact hepatic congestion limit heart failure patient treat prasugrel . The phase 3 , multi-center TRITON-TIMI 38 trial compare clopidogrel prasugrel show unselected patient population present ACS , prasugrel achieve great cardiovascular event reduction attribute robust platelet inhibition . Hence , design trial prospectively test hypothesis systolic heart failure patient increase circulate catecholamine possible abnormal functioning CYP450 system treat prasugrel achieve great platelet reactivity inhibition compare treated clopidogrel .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Patients 19 74 year age . Patients leave ventricular ejection fraction &lt; 35 % echocardiogram , SPECT myocardial perfusion study , cardiac MRI , cardiac computerize tomographic angiogram invasive leave ventricular angiogram within last 6 month . Patients NYHA Class IIIIV heart failure time enrollment . Recent hospitalization within 30 day Patients expect undergo major surgery PCI next 30 day Patients take clopidogrel , prasugrel , ticagrelor , ticlopidine , cilostazol Patients list heart transplantation leave ventricular assist device placement Patients know allergy either medication Patients prior history stroke transient ischemic attack Patients know intracranial neoplasm , aneurysm , arteriovenous malformation Patients history bleed require hospitalization treatment Patients take oral anticoagulant Patients body weight &lt; 60 kg Women pregnant breastfeeding Patients hemoglobin &lt; 10 mg/dl platelet count &lt; 100,000/ul baseline Patients know clot platelet disorder Patients baseline INR &gt; 1.4 Patients liver function test ( AST ALT ) &gt; 2 time normal Patients suspect change use aspirin study ( start , stop , change dose aspirin ) Patients unwilling consent CYP2C19 genetic testing .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Platelet aggregation</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Prasugrel</keyword>
</DOC>